Loading clinical trials...

Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer

Phase II Study of Bevacizumab and Erlotinib in Elderly Patients With Advanced Non-Small Lung Cancer

NCT00553800•Fox Chase Cancer Center

View on ClinicalTrials.gov

Summary

This study will evaluate the combination of bevacizumab and erlotinib in elderly patients with advanced non-small cell lung cancer.

Detailed Description

There is no definite evidence of a superior therapy for advanced non-small cell lung cancer in elderly patients. With the exception of one known study, single agent erlotinib has not been studied exclusively in the elderly and the combination of erlotinib and bevacizumab has never been studied exclusively in the treatment naive elderly. This is an important population that needs less toxic therapies.

Eligibility

Age

70 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Cytologically or histologic confirmed non-small cell lung cancer, stage IIIB or IV or recurrent after primary surgery or radiotherapy.
•ECOG PS 0-1
•70 years of age or older
•Must have measurable disease
•ANC \> 1500, platelets \> 100,000
•Total bilirubin \</= 1.5, SGOT \* SGPT \< 5 x ULN
•Able and willing to swallow and absorb oral medication
•Able and willing to sign consent
•Request archival diagnostic tissue for EGFR expression but not required

Exclusion Criteria

•Proteinuria as demonstrated by UPC ratio \>/= 1.0
•Prior treatment with an investigational or marketed inhibitor of the EGFR pathway or anti-angiogenesis agent (includes thalidomide)
•Prior treatment for advanced stage disease, with the exception of surgery or radiation (no systemic)
•History of gross hemoptysis within 1 month of enrollment unless treated with surgery or radiation
•Evidence of bleeding diathesis or coagulopathy or other serious/acute internal bleeding within 6 months of enrollment.
•Current, ongoing treatment with full dose warfarin or equivalent
•Current(within 10 days)use of aspirin (\> 325mg/day) or other NSAID with antiplatelet activity
•History of hemorrhagic or thrombotic stoke, TIA, or other CNS bleeding w/in last 6 months. Clinically significant PVD
•Known CNS disease except for treated brain mets.
•Squamous cell histology
+7 more criteria

Locations (7)

AtlantiCare Regional Medical Center

Galloway, New Jersey, United States

Fox Chase Virtua Health Cancer Program at Memorial

Mount Holly, New Jersey, United States

Paoli Hospital

Paoli, Pennsylvania, United States

Abramson Cnacer Center, University of Pennsylvania

Philadelphia, Pennsylvania, United States

Pennsylvania Oncology Hematology Associates

Philadelphia, Pennsylvania, United States

Fox Chase Cancer Center

Philadelphia, Pennsylvania, United States

Grand View Hospital

Sellersville, Pennsylvania, United States

Key Dates

Start Date

July 5, 2007

Primary Completion Date

January 12, 2011

Completion Date

June 1, 2011

Last Updated

July 12, 2022

Enrollment

ACTUAL participants

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

bevacizumab

DRUG

Erlotinib

DRUG

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

NCT06667908

Carcinoma, Non-Small-Cell Lung

View study

RECRUITING

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

NCT04165798

Carcinoma, Non-Small-Cell Lung

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 12, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer

Inclusion Criteria

Exclusion Criteria

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

A Study of LY4175408 in Participants With Advanced Cancer

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)